The Limited Times

Now you can see non-English news...

Covid: CureVac's vaccine candidate only 47% effective, according to interim analysis

2021-06-20T01:19:08.179Z


The messenger RNA vaccine does not meet the required criteria at this stage, said the German laboratory, which has signed a major ordering contract with the European Union.


German laboratory CureVac announced on Wednesday that its leading COVID-19 vaccine candidate had only shown 47% efficacy, according to the interim analysis of a large-scale clinical trial, and was not fulfilling at this stage. the required criteria.

Read also: Covid: what is the ideal time between the two doses of vaccine?

The vaccine

"has reached a preliminary efficacy of 47% against COVID-19, regardless of its severity, not meeting the pre-specified statistical criteria of success

,

"

said in a statement the laboratory which signed a major contract of order with the European Union for this messenger RNA vaccine.

Source: lefigaro

All business articles on 2021-06-20

You may like

News/Politics 2024-03-16T18:46:42.470Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.